Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer
(2014) In Science Signaling 7(318). p.1-9- Abstract
Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway are common and therapeutically targeted in triple-negative breast cancer (TNBC). However, activation of another EGFR family member [human epidermal growth factor receptor 3 (HER3) (or ErbB3)] may limit the antitumor effects of these drugs. We found that TNBC cell lines cultured with the EGFR or HER3 ligand EGF or heregulin, respectively, and treated with either an Akt inhibitor (GDC- 0068) or a PI3K inhibitor (GDC-0941) had increased abundance and phosphorylation of HER3. The phosphorylation of HER3 and EGFR in response to these treatments was reduced by the addition of a dual EGFR and HER3 inhibitor... (More)
Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway are common and therapeutically targeted in triple-negative breast cancer (TNBC). However, activation of another EGFR family member [human epidermal growth factor receptor 3 (HER3) (or ErbB3)] may limit the antitumor effects of these drugs. We found that TNBC cell lines cultured with the EGFR or HER3 ligand EGF or heregulin, respectively, and treated with either an Akt inhibitor (GDC- 0068) or a PI3K inhibitor (GDC-0941) had increased abundance and phosphorylation of HER3. The phosphorylation of HER3 and EGFR in response to these treatments was reduced by the addition of a dual EGFR and HER3 inhibitor (MEHD7945A). MEHD7945A also decreased the phosphorylation (and activation) of EGFR and HER3 and the phosphorylation of downstream targets that occurred in response to the combination of EGFR ligands and PI3K-Akt pathway inhibitors. In culture, inhibition of the PI3K-Akt pathway combined with either MEHD7945A or knockdown of HER3 decreased cell proliferation compared with inhibition of the PI3K-Akt pathway alone. Combining either GDC-0068 orGDC-0941 with MEHD7945A inhibited the growth of xenografts derived from TNBC cell lines or from TNBC patient tumors, and this combination treatment was also more effective thancombining eitherGDC-0068 orGDC-0941 with cetuximab, anEGFR-targeted antibody.After therapy with EGFR-targeted antibodies, some patients had residual tumors with increased HER3 abundance and EGFR/HER3 dimerization (an activating interaction). Thus, we propose that concomitant blockade of EGFR, HER3, and the PI3K-Akt pathway in TNBC should be investigated in the clinical setting.
(Less)
- author
- organization
- publishing date
- 2014-03-25
- type
- Contribution to journal
- publication status
- published
- in
- Science Signaling
- volume
- 7
- issue
- 318
- article number
- ra29
- pages
- 1 - 9
- publisher
- American Association for the Advancement of Science (AAAS)
- external identifiers
-
- scopus:84897133359
- pmid:24667376
- ISSN
- 1945-0877
- DOI
- 10.1126/scisignal.2005125
- language
- English
- LU publication?
- no
- id
- 658ef754-ba6e-4598-adc4-d1aa632e8397
- date added to LUP
- 2016-12-02 16:11:26
- date last changed
- 2024-04-19 13:58:51
@article{658ef754-ba6e-4598-adc4-d1aa632e8397,
abstract = {{<p>Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway are common and therapeutically targeted in triple-negative breast cancer (TNBC). However, activation of another EGFR family member [human epidermal growth factor receptor 3 (HER3) (or ErbB3)] may limit the antitumor effects of these drugs. We found that TNBC cell lines cultured with the EGFR or HER3 ligand EGF or heregulin, respectively, and treated with either an Akt inhibitor (GDC- 0068) or a PI3K inhibitor (GDC-0941) had increased abundance and phosphorylation of HER3. The phosphorylation of HER3 and EGFR in response to these treatments was reduced by the addition of a dual EGFR and HER3 inhibitor (MEHD7945A). MEHD7945A also decreased the phosphorylation (and activation) of EGFR and HER3 and the phosphorylation of downstream targets that occurred in response to the combination of EGFR ligands and PI3K-Akt pathway inhibitors. In culture, inhibition of the PI3K-Akt pathway combined with either MEHD7945A or knockdown of HER3 decreased cell proliferation compared with inhibition of the PI3K-Akt pathway alone. Combining either GDC-0068 orGDC-0941 with MEHD7945A inhibited the growth of xenografts derived from TNBC cell lines or from TNBC patient tumors, and this combination treatment was also more effective thancombining eitherGDC-0068 orGDC-0941 with cetuximab, anEGFR-targeted antibody.After therapy with EGFR-targeted antibodies, some patients had residual tumors with increased HER3 abundance and EGFR/HER3 dimerization (an activating interaction). Thus, we propose that concomitant blockade of EGFR, HER3, and the PI3K-Akt pathway in TNBC should be investigated in the clinical setting.</p>}},
author = {{Tao, Jessica J. and Castel, Pau and Radosevic-Robin, Nina and Elkabets, Moshe and Auricchio, Neil and Aceto, Nicola and Weitsman, Gregory and Barber, Paul and Vojnovic, Borivoj and Ellis, Haley and Morse, Natasha and Viola-Villegas, Nerissa Therese and Bosch Campos, Ana and Juric, Dejan and Hazra, Saswati and Singh, Sharat and Kim, Phillip and Bergamaschi, Anna and Maheswaran, Shyamala and Ng, Tony and Penault-Llorca, Frédérique and Lewis, Jason S. and Carey, Lisa A. and Perou, Charles M. and Baselga, José and Scaltriti, Maurizio}},
issn = {{1945-0877}},
language = {{eng}},
month = {{03}},
number = {{318}},
pages = {{1--9}},
publisher = {{American Association for the Advancement of Science (AAAS)}},
series = {{Science Signaling}},
title = {{Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer}},
url = {{http://dx.doi.org/10.1126/scisignal.2005125}},
doi = {{10.1126/scisignal.2005125}},
volume = {{7}},
year = {{2014}},
}